Second-generation direct-acting-antiviral hepatitis C virus treatment: Efficacy, safety, and predictors of SVR12

相似書籍

• First-generation protease inhibitor-triple therapy: SVR 24, safety, and predictors of response in a large single center cohort
  由: Werner, Christoph R, et al.
  出版: (2015)
• Feasibility of Telaprevir-Based Triple Therapy in Liver Transplant Patients with Hepatitis C Virus: SVR 24 Results
  由: Werner, Christoph R., et al.
  出版: (2013)
• Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals
  由: Lin, Chuan-Pin, et al.
  出版: (2021)
• Successful direct acting antiviral (DAA) treatment of HCV/HIV-coinfected patients before and after liver transplantation
  由: Grottenthaler, Julia M., et al.
  出版: (2018)
• High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
  由: Fu, Zuqiang, et al.
  出版: (2021)